Filing Details

---

1	NAMES OF REPORTING PERSONS
	Glenview Capital Management, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			17,078,657(1)
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			17,078,657(1)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	17,078,657(1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	4.75%(2)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	OO

1	NAMES OF REPORTING PERSONS
	Larry Robbins
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☐
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			17,078,657(1)
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			17,078,657(1)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	17,078,657(1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	4.75%(2)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN, HC

(1)	Includes 1,728,700 Shares underlying Call Options.

(2)	Based on a total of 359,330,757 Shares outstanding as of October 28, 2021, based on the Issuer’s Quarterly Report on Form 10-Q, filed November 2, 2021.

Item 1 of the Schedule 13D is hereby amended and supplemented as follows:

This Amendment No. 1 to the Schedule 13D (“Amendment No. 1”) amends and supplements the information set forth in the Schedule 13D filed by the Reporting Persons with the U.S. Securities and Exchange Commission (the “SEC”) on July 27, 2020 (the “Original Schedule 13D” and collectively, the “Schedule 13D”), relating to the common shares, no par value (“Shares”), of Bausch Health Companies Inc., a corporation organized under the laws of British Columbia, Canada (the “Issuer”), whose principal executive offices are located at 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D.

Item 2(a-c, f) of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a-c, f) This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

i) Glenview Capital Management, LLC (“Glenview Capital Management”); and

ii) Larry Robbins (“Mr. Robbins”).

This Statement relates to Shares held for the accounts of Glenview Capital Partners, L.P., a Delaware limited partnership (“Glenview Capital Partners”), Glenview Capital Master Fund, Ltd., a Cayman Islands exempted company (“Glenview Capital Master Fund”), Glenview Institutional Partners, L.P., a Delaware limited partnership (“Glenview Institutional Partners”), Glenview Offshore Opportunity Master Fund, Ltd., a Cayman Islands exempted company (“Glenview Offshore Opportunity Master Fund”), Glenview Capital Opportunity Fund, L.P., a Delaware limited partnership (“Glenview Capital Opportunity Fund”) and Glenview Healthcare Master Fund, L.P. (“Glenview Healthcare Master Fund” and, together with Glenview Capital Partners, Glenview Capital Master Fund, Glenview Institutional Partners, Glenview Offshore Opportunity Master Fund and Glenview Capital Opportunity Fund, the “Glenview Funds”).

Glenview Capital Management serves as investment manager to each of Glenview Capital Partners, Glenview Capital Master Fund, Glenview Institutional Partners, Glenview Offshore Opportunity Master Fund, Glenview Capital Opportunity Fund and Glenview Healthcare Master Fund.  Mr. Robbins is the Chief Executive Officer of Glenview Capital Management.

The address of the principal business office of each of Glenview Capital Management and Mr. Robbins is 767 Fifth Avenue, 44th Floor, New York, New York 10153.

Glenview Capital Management is a Delaware limited liability company; Mr. Robbins is a citizen of the United States of America.

Item 5 of the Schedule 13D is hereby amended and supplemented as follows:

(a, b) As of December 9, 2021, each of Glenview Capital Management and Mr. Robbins may be deemed to the beneficial owner of 17,078,657 Shares, which amount consists of 15,349,957 Shares over which Glenview Capital Management and Mr. Robbins share voting and investment power over, and 1,728,700 Shares underlying 17,287 Call Options. As of December 9, 2021, each of Glenview Capital Management and Mr. Robbins may be deemed the beneficial owner of approximately 4.75% of the total number of Shares outstanding. The beneficial ownership percentage is based on a total of 359,330,757 Shares outstanding as of October 28, 2021, based on the Issuer’s Quarterly Report on Form 10-Q, filed November 2, 2021.

The 17,078,657 Shares reported herein consists of: (A) 446,866 Shares held for the account of Glenview Capital Partners; (B) 28,500 Shares underlying 285 Call Options held for the account of Glenview Capital Partners; (C) 3,562,588 Shares held for the account of Glenview Capital Master Fund; (D) 1,179,891 Shares held for the account of Glenview Institutional Partners; (E) 11,600 Shares underlying 116 Call Options held for the account of Glenview Institutional Partners; (F) 3,311,854 Shares held for the account of Glenview Offshore Opportunity Master Fund; (G) 823,800 Shares underlying 8,238 Call Options held for the account of Glenview Offshore Opportunity Master Fund; (H) 6,595,352 Shares held for the account of Glenview Capital Opportunity Fund; (I) 864,800 Shares underlying 8,648 Call Options held for the account of Glenview Capital Opportunity Fund; and (J) 253,406 Shares held for the account of Glenview Healthcare Master Fund.

(c) Except for the transactions listed in Exhibit D hereto, each of which was effected in the open market in routine brokerage transactions, there have been no transactions in Shares, or derivatives thereon, by the Reporting Persons during the past 60 days.

(d) The Glenview Funds are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares and Call Options covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

(e) The Reporting Persons are no longer the beneficial owners of more than five percent of the Common Stock outstanding.

Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 13, 2021